Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Macitentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Macitentan SCHEMBL1445625 | 1.00 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380505 | 0.94 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569175 | 0.94 | EDNRA (0.89) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569156 | 0.94 | EDNRA (0.89) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569102 | 0.93 | EDNRA (0.88) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380529 | 0.93 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL23876322 | 0.93 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380521 | 0.93 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.92 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380524 | 0.92 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116847-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2024-04-11 | — | — | US | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605080-A1 | TREATMENT OF MITOCHONDRIAL DISEASES WITH SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250243228-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12365663-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250205173-A1 | DERMAL AND TRANSDERMAL ADMINISTRATION OF TREPROSTINIL AND SALTS THEREOF | Corsair Pharma, Inc. | 2025-06-26 | — | — | US | disclosed |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240366596-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20220112173-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220096476-A1 | Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension | ACTELION PHARMACEUTICALS LTD (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20220096476-A1 | Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension | ACTELION PHARMACEUTICALS LTD (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20220096474-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | ACTELION PHARMACEUTICALS LTD. (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20220096474-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | ACTELION PHARMACEUTICALS LTD. (CH) | 2022-03-31 | — | — | US | disclosed |
| WO-2022045991-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACITENTAN AND RELEVANT EXCIPIENTS | PHARMACTİVE İLAÇ SANAYİ VE TİCARET A.Ş. (TR) | 2022-03-03 | — | — | WO | disclosed |
| US-20220055980-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3946347-A1 | MACITENTAN FOR USE IN TREATING PORTOPULMONARY HYPERTENSION | Actelion Pharmaceuticals Ltd (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-11234980-B2 | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | ACTELION PHARMACEUTICALS LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| US-11234980-B2 | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | ACTELION PHARMACEUTICALS LTD (CH) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116847-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | EDNRA 150/4885EDNRB 110/4885SLC6A2 835/4885 |
| US-20240366596-A1 | TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATOR | GUCY1A2, GUCY1A1, GUCY1B2 | EDNRA 43/4885EDNRB 37/4885SLC6A2 2681/4885 |
| US-11234980-B2 | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | PDE5A, PDE3A, PDE2A | EDNRA 28/4885EDNRB 65/4885SLC6A2 1608/4885 |
| US-20250205173-A1 | DERMAL AND TRANSDERMAL ADMINISTRATION OF TREPROSTINIL AND SALTS THEREOF | TSLP, PTGIS, PTGIR | EDNRA 72/4885EDNRB 68/4885SLC6A2 47/4885 |
| US-20220055980-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | EDNRA 150/4885EDNRB 110/4885SLC6A2 835/4885 |
| US-20250243228-A1 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | P2RY1, P2RY11, GMPS | EDNRA 173/4885EDNRB 203/4885SLC6A2 2544/4885 |
| US-20220096474-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION | PDE9A, PDE3A, PTGIS | EDNRA 15/4885EDNRB 58/4885SLC6A2 2452/4885 |
| US-20250129060-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | EDNRA 245/4885EDNRB 279/4885SLC6A2 2492/4885 |
| US-12365663-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | EDNRA 55/4885EDNRB 32/4885SLC6A2 757/4885 |
| US-20220096476-A1 | Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension | PDE5A, PDE3A, PDE2A | EDNRA 28/4885EDNRB 65/4885SLC6A2 1608/4885 |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | EDNRA 181/4885EDNRB 292/4885SLC6A2 541/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | EDNRA 100/4885EDNRB 98/4885SLC6A2 3145/4885 |
| US-20220112173-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | EDNRA 55/4885EDNRB 32/4885SLC6A2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.